Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- Your tumor tests positive for two specific proteins: CLDN18.2 (in at least 75% of cells) and PD-L1 (CPS score of 1 or higher).
- You have not had chemotherapy or immunotherapy for advanced cancer, except possibly a short course (up to 2 weeks) of one chemo type.
- You are able to walk and care for yourself (ECOG score 0 or 1), and your doctor believes you will live at least 3 more months.
- You do not have certain other health conditions like active infections, severe heart problems, or untreated ulcers.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.